AA
SABS icon

ALPS Advisors’s SAB Biotherapeutics SABS Stock Holding History

ALPS Advisors’s Portfolio SABS Stock Details SABS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-4,508
Closed -$170K – 1083
2022
Q1 		$170K Sell
4,508
-523
-10% -$24.1K ﹤0.01% 812
2021
Q4 		$393K Buy
+5,031
New +$472K ﹤0.01% 682

Other funds holding SABS

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FPB
First PREMIER Bank Sioux Falls, South Dakota $619M AUM 20.21% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MC
Meteora Capital Boca Raton, Florida $1.36B AUM 21.19% 1-Year Est. Return
SCM
Shaolin Capital Management Miami, Florida $2.71B AUM 64.83% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
IFAM
Institutional & Family Asset Management Fort Collins, Colorado $654M AUM 12.29% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

ALPS Advisors's SABS Position: Q2 2022 in Review

ALPS Advisors sold out of SAB Biotherapeutics (SABS) in Q2 2022, closing a stake of 4,508 shares — an estimated $170K sold.

ALPS Advisors first reported a position in SABS in Q4 2021 and held it in 2 quarters. The position peaked at $393K in Q4 2021. 37 funds tracked by Wall St. Rank hold SABS as of Q2 2022.

  • ALPS Advisors reported no remaining SAB Biotherapeutics position as of Q2 2022 after selling out during the quarter.
  • ALPS Advisors sold 4,508 SAB Biotherapeutics shares in Q2 2022, an estimated $170K.
  • ALPS Advisors first reported a position in SAB Biotherapeutics in Q4 2021 and held it in 2 quarters.
  • ALPS Advisors's SAB Biotherapeutics position peaked at $393K in Q4 2021.
  • 37 funds tracked by Wall St. Rank held SAB Biotherapeutics as of Q2 2022.

Based on ALPS Advisors's 13F filing for Q2 2022, filed 11 Aug 2022.